Today: 19 April 2026
Red Cat Holdings Stock Swings After Pentagon Drone Results Cool Rally Ahead of March 18 Earnings

Red Cat Holdings Stock Swings After Pentagon Drone Results Cool Rally Ahead of March 18 Earnings

NEW YORK, March 9, 2026, 10:42 EDT

Red Cat Holdings shares whipsawed Monday, losing ground after a public Drone Dominance leaderboard named 11 contenders for prototype contracts. SUAS News still counted the company’s Teal Drones unit in the mix, but the fresh list cooled a rally that had just sent the stock to its highest point in a year last week. By mid-morning, shares had fallen roughly 4%—opening at $16.08, peaking at $16.78, and then sliding to $14.74. On Friday, they’d tagged $18.78, the stock’s highest mark in the last year.

This turnaround is significant: Washington has stepped up buying low-cost, single-use attack drones—these are built to strike and not come back. Just last week, Reuters broke the news that the U.S. deployed a bargain attack drone in Iran, highlighting the rapid pace in the market Red Cat is targeting.

Red Cat is casting a wider net with investors. On March 2, the company announced Allen Control Systems had come aboard its Futures Initiative. The first Bullfrog counter-drone tech will be integrated into Blue Ops, Red Cat’s maritime arm—part of the company’s effort to stretch past small ISR drones into a full-scale, multi-domain lineup. “Equally advanced countermeasures” are needed to match the rapid spread of small unmanned systems, said Jason Gunter, Red Cat’s vice president of technology and innovation. Red Cat Holdings, Inc.

Jeff Thompson, the chief executive, put an even finer point on it over the weekend. Speaking to Schwab Network in an interview published Sunday, he suggested the Strait of Hormuz could stay under watch “for years to come.” Thompson also said, “Bring us that demand and we’ll ship it right away.” Schwab Network

Red Cat’s upcoming numbers could either validate the current narrative or blow holes in it. Back in January, the company flagged preliminary fourth-quarter revenue between $24 million and $26.5 million—a jump of roughly 1,842% from a year ago. For full-year 2025, the forecast landed at $38 million to $41 million. But as noted in an 8-K, those totals were unaudited and could shift when results drop on March 18.

Needham’s Austin Bohlig stuck with his Buy rating and $16 target on Red Cat after Innovation Day. Bohlig said he came away “meaningfully more impressed” by the multi-domain platform and more positive on the company’s 2026 outlook. Streetwise Reports, which recapped Bohlig’s call, noted Needham had investment-banking ties to Red Cat in the past year and currently makes a market in the shares. Streetwise Reports

Competition is thick. According to Reuters, the Pentagon’s drive for cheaper, faster drones has drawn big names like AeroVironment into the mix with a host of upstart firms. Kratos, for its part, has been running tests of budget-friendly attack drones over in Taiwan. Teal Drones, meanwhile, snagged a spot as one of just 25 suppliers brought into Gauntlet I.

Risks aren’t exactly hidden here. Red Cat’s most recent quarterly filing shows $9.6 million in revenue for the September quarter, gross profit at $637,502—just 7%—and a net loss from continuing operations totaling $16 million. For the first nine months of 2025, the company burned through $52.7 million in cash on operating activities. Bohlig said cash burn may stay high into the first half of 2026 as factory expansions continue. Red Cat has also cautioned that its January revenue could “materially differ” from audited results. Red Cat Holdings, Inc.

Right now, it’s still all about execution. Back in August, the Army listed Teal Drones and its Black Widow platform as suppliers for the Short Range Reconnaissance program. By February, Red Cat reported it had secured a fresh Black Widow order from an Asia-Pacific ally, set for delivery in 2026. How those deals shake out—specifically, whether they lead to ongoing, reliable output—is what investors are currently trying to figure out.

Stock Market Today

  • Ford, GM, Stellantis Stocks Rise in Week Ending April 17
    April 19, 2026, 9:06 AM EDT. Ford Motor Co., General Motors, and Stellantis posted stock gains for the week ending April 17, 2026. Ford's shares rose 6.1% to $12.87, General Motors increased 6.41% to $81.32, and Stellantis climbed 7.21% to $8.62. The Detroit Three automakers experienced notable stock price fluctuations during the week amid broader market dynamics. Investors responded to sector developments, including leadership changes at Ford, defense collaborations involving GM and Ford, and Stellantis' strong North American vehicle shipments. Market hours run from 9:30 a.m. to 4 p.m. Eastern Time, Monday through Friday.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 19.04.2026

19 April 2026
LIVEMarkets rolling coverageStarted: April 19, 2026, 12:00 AM EDTUpdated: April 19, 2026, 9:11 AM EDT Ford, GM, Stellantis Stocks Rise in Week Ending April 17 April 19, 2026, 9:06 AM EDT.Ford Motor Co., General Motors, and Stellantis posted stock gains for the week ending April 17, 2026. Ford's shares rose 6.1% to $12.87, General Motors increased 6.41% to $81.32, and Stellantis climbed 7.21% to $8.62. The Detroit Three automakers experienced notable stock price fluctuations during the week amid broader market dynamics. Investors responded to sector developments, including leadership changes at Ford, defense collaborations involving GM and Ford, and Stellantis' strong
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds
Previous Story

Capricor Therapeutics Stock Rises Ahead of March 12 Update as FDA Watch on Duchenne Drug Builds

Jefferies Financial Group Inc Says MFS Losses Seen Under $20 Million as Western Alliance Clash Deepens
Next Story

Jefferies Financial Group Inc Says MFS Losses Seen Under $20 Million as Western Alliance Clash Deepens

Go toTop